

# UNIVERSITY OF COLORADO CANCER CENTER

Hematology-Oncology  
1665 Aurora Court, Aurora CO 80045  
Phone: 720-555-0500 | Fax: 720-555-0501  
NPI: 1567893421

February 01, 2026

Blue Cross Blue Shield  
Federal Employee Program  
Prior Authorization Department  
Medical Review Unit

## RE: Letter of Medical Necessity

Patient Name:	Robert Hawkins
Date of Birth:	1971-11-03
Member ID:	FEP891245637
Group Number:	FEP-STANDARD-2024
Medication Requested:	Lisocabtagene maraleucel (Breyanzi)
Diagnosis:	Diffuse large B-cell lymphoma, unspecified site (C83.30)

To Whom It May Concern:

I am writing on behalf of my patient, Robert Hawkins, to document the medical necessity of Lisocabtagene maraleucel (Breyanzi) for the treatment of Diffuse large B-cell lymphoma, unspecified site. This letter provides clinical documentation supporting the need for this medication and demonstrates that my patient meets the coverage criteria for this therapy.

## CLINICAL HISTORY AND DIAGNOSIS

54-year-old male with relapsed/refractory DLBCL and pre-existing mild congestive heart failure (HFmrEF, LVEF 45%). Originally diagnosed June 2024 with Stage IIIA DLBCL. Due to cardiac comorbidity (LVEF 45%, borderline for anthracycline use), first-line therapy was R-bendamustine (rituximab + bendamustine) x6 cycles instead of standard R-CHOP — doxorubicin was contraindicated per cardiology consultation. Achieved partial response but relapsed at 6 months. Second-line R-GemOx (rituximab, gemcitabine, oxaliplatin) x4 cycles with progressive disease. Not eligible for autologous transplant due to cardiac status. Now referred for CAR-T cell therapy.

## CURRENT DISEASE ACTIVITY

Most recent assessment (2026-01-20):

- Ann Arbor Stage: IIIA
- Ecog Performance Status: 1
- Ecog Interpretation: Restricted in physically strenuous activity but ambulatory
- Ipi Score: 2
- Ipi Risk Category: Low-intermediate
- Disease Status: relapsed\_refractory
- Lines Of Therapy Completed: 2

## PRIOR TREATMENT HISTORY

The patient has tried and/or completed the following therapies:

- R-Bendamustine** (2024-07-01 to 2024-12-15)

Outcome: Partial response (Deauville 3) at end of treatment. Used instead of R-CHOP due to cardiac contraindication to doxorubicin (anthracycline). Relapsed at 6 months with new supraclavicular and inguinal lymphadenopathy.

- R-GemOx** (2025-07-01 to 2025-10-15)

Outcome: Progressive disease on restaging PET/CT with new hepatic and splenic lesions. Biopsy confirmed persistent DLBCL.

#### **MEDICAL NECESSITY SUMMARY**

Based on the clinical evidence presented, Lisocabtagene maraleucel (Breyanzi) is medically necessary for Robert Hawkins. The patient has a confirmed diagnosis of Diffuse large B-cell lymphoma, unspecified site (ICD-10: C83.30). Key criteria met: Biopsy-confirmed DLBCL (ICD-10 C83.30), CD19-positive; Patient is 54 years old ( $\geq 18$ ); Rituximab included in both prior lines (R-bendamustine, R-GemOx); 2 prior lines of systemic therapy completed. I respectfully request approval of this prior authorization.

Please contact my office if you require any additional clinical information.

Sincerely,

---

**Dr. Kevin Patel, MD, FACP**

Hematology-Oncology

NPI: 1567893421

Date: 02/01/2026